1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
  5. > Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update

The Competitive Intelligence Report „Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update“ provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) for treatment of a variety of cancer indications and retinal diseases as of February 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) are a highly successful class of products as evidenced by total sales of  US$ 15 bln in 2015. While Avastin has been known for years as a blockbuster biologic, anti-VEGF products Lucentis and Eylea for treatment of retinal diseases posted for the first time in 2015 higher sales than the anti-VEGF/R products for cancer treatment. The commercial success of Avastin as a single product approved for many cancer indications and the forthcoming patent expiries in the major markets have attracted a number of biosimilar developments in advanced clinical stages.

Until now, less attention has been paid to anti-VEGF antibodies used for treatment of ophthalmic diseases although the approved antibody products are attractive targets for the second wave of biosimilar antibodies because of the impressive market growth fueled by the clinical success and patent expiries in the mid-term.

The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies or proteins for treatment of cancer and neo-angiogenic eye diseases. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - a 2016 Update

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - a 2016 Update


Table of Contents


1) Marketed Anti-VEGF/R Products in Oncology



  • Avastin, Zaltrap andamp; Cyramza Sales 2008 - 2015

  • Avastin Sales and Indication Portfolio

  • Zaltrap Sales and Indication Portfolio

  • Cyramza Sales and Indication Portfolio


2) Anti-VEGF Biosuperiors of Avastin and Zaltrap



  • Anti-VEGF Biosuperior Pipeline in Oncology

  • Bispecific Anti-VEGF Pipeline in Oncology


3) Anti-VEGF-R Biosuperiors of Cyramza



  • Anti-VEGF-R Biosuperior Pipeline in Oncology

  • Bispecific Anti-VEGF-R Pipeline in Oncology


4) Avastin Biosimilar Pipeline in Oncology


5) Marketed Anti-VEGF Products in Ophthalmology



  • Lucentis andamp; Eylea Sales 2008 - 2015

  • Lucentis Sales andamp; Indication Portfolio

  • Eylea Sales andamp; Indication Portfolio


6) Anti-VEGF Biosuperiors of Lucentis and Eylea



  • Biosuperior Anti-VEGF in Ophthalmology

  • Biosuperior Bispecific Anti-VEGF and Anti-VEGF Combinations in Ophthalmology


7) Other Anti-VEGF Molecules in Ophthalmology


8) Lucentis Biosimilars in Ophthalmology


9) Eylea Biosimilars in Ophthalmology


10) Off-Label Use of Anti-VEGF in Ophthalmology

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Sunitinib Malate Market: By Disease (Pancreatic Neuroendocrine Tumors & Kidney Cancer) & By Region (Europe, North America, Asia-Pacific & Rest of the World (RoW))-Forecast (2016-2021)

Sunitinib Malate Market: By Disease (Pancreatic Neuroendocrine Tumors & Kidney Cancer) & By Region (Europe, North America, Asia-Pacific & Rest of the World (RoW))-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Sunitinib, developed and marketed as Sutent by Pfizer Inc and previously known as SU11248, is a small-molecule medicine which has to be administered orally and has been proven to be effective in blocking ...

Global Kinase Inhibitors Market Report 2016

Global Kinase Inhibitors Market Report 2016

  • $ 2850
  • Industry report
  • August 2016
  • by 9Dimen Research

2016 Global Kinase Inhibitors Report is a professional and in-depth research report on the world's major regional market conditions of the Kinase Inhibitors industry, focusing on the main regions (North ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.